Investigational Drug Information for MN-166
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug MN-166?
MN-166 is an investigational drug.
There have been 12 clinical trials for MN-166.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 28th 2020.
The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Alcohol Abuse and Alcoholism (NIAAA).
There are eight hundred and six US patents protecting this investigational drug and seven international patents.
Summary for MN-166
| US Patents | 806 |
| International Patents | 7,872 |
| US Patent Applications | 3,593 |
| WIPO Patent Applications | 1,375 |
| Japanese Patent Applications | 1,295 |
| Clinical Trial Progress | Phase 2 (2020-05-28) |
| Vendors | 96 |
Recent Clinical Trials for MN-166
| Title | Sponsor | Phase |
|---|---|---|
| A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder | University of Pennsylvania | Phase 2 |
| Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS | MediciNova | Phase 2 |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | MediciNova | Phase 2/Phase 3 |
Clinical Trial Summary for MN-166
Top disease conditions for MN-166
Top clinical trial sponsors for MN-166
US Patents for MN-166
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MN-166 | See Plans and Pricing | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | See Plans and Pricing |
| MN-166 | See Plans and Pricing | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | See Plans and Pricing |
| MN-166 | See Plans and Pricing | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | See Plans and Pricing |
| MN-166 | See Plans and Pricing | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | The Catholic University of America (Washington, DC) | See Plans and Pricing |
| MN-166 | See Plans and Pricing | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MN-166
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MN-166 | Canada | CA2961033 | 2034-09-11 | See Plans and Pricing |
| MN-166 | European Patent Office | EP3192791 | 2034-09-11 | See Plans and Pricing |
| MN-166 | Japan | JPWO2016039408 | 2034-09-11 | See Plans and Pricing |
| MN-166 | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | See Plans and Pricing |
| MN-166 | Australia | AU2012222348 | 2031-03-01 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
